If you have not received a direct call about altering your child’s appointment, it will continue as scheduled.
Eric S. Schafer, MD, MHS
- Texas Medical Center
- Developmental therapeutics
Assistant Professor, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine
|Johns Hopkins University / National Cancer Institute||fellowship||Pediatric Hematology Oncology||2010|
|Children's Hospital of Philadelphia||residency||Pediatrics||2006|
|Baylor College of Medicine||medical school||Doctor of Medicine||2003|
|Johns Hopkins Bloomberg School of Public Health||university|
Dr. Eric Schafer is a member of the Leukemia Program and the Developmental Therapeutics Program. His clinical interests include caring for children with leukemias and children with all cancer types requiring novel therapies. His research interests focus on studying the clinical development of new cancer drugs for children and exploring new ways to make older drug safer and more effective.
In addition to his training and certification in Pediatrics and Pediatric Hematology/Oncology, Dr. Schafer is fellowship trained and board certified in Clinical Pharmacology. He has used this training and interest to lead several local and national studies on standard drugs including vincristine and methotrexate and new drugs such as talazoparib and eribulin.
Dr. Schafer is an active member of the Children’s Oncology Group (COG) where he serves on protocol study committees for T cell ALL and high risk pre-B ALL and is an active member of the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) consortium for which he serves as the Texas Children’s Cancer Center’s Principal Investigator.
American Board of Pediatrics
American Board of Pediatrics – Hematology/Oncology
American Board of Clinical Pharmacology
|American Academy of Pediatrics (AAP)||Member|
|American Society of Hematology (ASH)||Member|
|American Society of Pediatric Hematology/Oncology (ASPHO)||Member|
|Children's Oncology Group (COG)||Member|
|Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL)||Member|
Norton Rose Fulbright Faculty Excellence Award for Teaching and Evaluation, Baylor College of Medicine, 2019